Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Abroad (travel likely)RecruitingPHASE3

Conditions

Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Dongmei Ji, M.D) · jidongmei2000@126.com · +8602164175590

Study leads

Dongmei Ji, M.D
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma · High-Risk Cancer · Maintenance Therapy

Abroad (travel likely)RecruitingPHASE3

Ganzhou, China · Guangzhou, China

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma (NPC)

Abroad (travel likely)RecruitingPHASE3

Nanning, China

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Fuzhou, China · Xiamen, China